These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6694161)

  • 1. Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
    Kennedy PE; Williams FL; Abraham DJ
    J Med Chem; 1984 Feb; 27(2):103-5. PubMed ID: 6694161
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
    Sablayrolles M; Wajcman H; Castaigne JP; Labie D
    Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 6. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site.
    Chatterjee R; Iwai Y; Walder RY; Walder JA
    J Biol Chem; 1984 Dec; 259(23):14863-73. PubMed ID: 6501320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
    Abraham DJ; Mehanna AS; Williams FS; Cragoe EJ; Woltersdorf OW
    J Med Chem; 1989 Nov; 32(11):2460-7. PubMed ID: 2810334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
    Fatope MO; Abraham DJ
    J Med Chem; 1987 Nov; 30(11):1973-7. PubMed ID: 3669005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand kinetics of hemoglobin S containing erythrocytes.
    Harrington JP; Elbaum D; Bookchin RM; Wittenberg JB; Nagel RL
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):203-6. PubMed ID: 264675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and testing of potential antisickling agents. 6. Rheologic studies with active phenoxy and benzyloxy acids.
    Patwa DC; Abraham DJ; Hung TC
    Blood Cells; 1987; 12(3):589-601. PubMed ID: 3651614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of ethacrynic acid, dihydroethacrynic acid and certain thiol adducts of ethacrynic acid with bovine serum albumin.
    Koechel DA; Smith SA; Cafruny EJ
    J Pharmacol Exp Ther; 1977 Nov; 203(2):272-82. PubMed ID: 909062
    [No Abstract]   [Full Text] [Related]  

  • 13. Membrane modifiers in sickle cell disease.
    Benjamin LJ
    Ann N Y Acad Sci; 1989; 565():247-61. PubMed ID: 2672964
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of pyridine derivatives of L-phenylalanine as antisickling reagents.
    Altman J; Gorecki M; Wilchek M; Votano JR; Rich A
    J Med Chem; 1984 May; 27(5):596-600. PubMed ID: 6716398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid.
    Walder JA; Zaugg RH; Iwaoka RS; Watkin WG; Klotz IM
    Proc Natl Acad Sci U S A; 1977 Dec; 74(12):5499-503. PubMed ID: 271972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl acetyl phosphate, a new type of antisickling agent: site-specific acetylating agent toward the 2,3-DPG binding site in hemoglobin S.
    Ueno H; Manning JM
    Am J Pediatr Hematol Oncol; 1988; 10(4):348-50. PubMed ID: 3239714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of antisickling compounds that chemically modify hemoglobin S specifically within the 2,3-diphosphoglycerate binding site.
    Walder JA; Walder RY; Arnone A
    J Mol Biol; 1980 Aug; 141(2):195-216. PubMed ID: 7441751
    [No Abstract]   [Full Text] [Related]  

  • 19. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "Split" Hemoglobin S Peak.
    Colby JM; Shajani-Yi Z
    Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.